

# Ahmad A Tarhini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3924929/publications.pdf>

Version: 2024-02-01

138  
papers

8,322  
citations

81900

39  
h-index

54911

84  
g-index

143  
all docs

143  
docs citations

143  
times ranked

11570  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	27.0	983
2	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	27.6	831
3	Immunotherapy of cancer in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 309-335.	329.8	379
4	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1744.	7.4	312
5	Baseline circulating IL-17 predicts toxicity while TGF- $\beta$ 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. , 2015, 3, 39.		302
6	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. <i>PLoS ONE</i> , 2014, 9, e87705.	2.5	261
7	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
8	Next Generation of Immunotherapy for Melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3445-3455.	1.6	215
9	Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy. <i>Journal of Clinical Oncology</i> , 2002, 20, 3703-3718.	1.6	194
10	Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. <i>Scientifica</i> , 2013, 2013, 1-19.	1.7	186
11	Anticancer Cytokines: Biology and Clinical Effects of Interferon- $\gamma$ 2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. <i>Seminars in Oncology</i> , 2015, 42, 539-548.	2.2	179
12	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598.	27.6	177
13	Prognostic significance of autoimmunity during treatment of melanoma with interferon. <i>Seminars in Immunopathology</i> , 2011, 33, 385-391.	6.1	143
14	Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 632-646.	0.8	132
15	Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 322-328.	1.6	131
16	High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. , 2014, 2, 26.		130
17	Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 601-613.	1.0	125
18	An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles. <i>Cancer Cell</i> , 2019, 35, 33-45.e6.	16.8	125

#	ARTICLE	IF	CITATIONS
19	Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. <i>Journal of Clinical Oncology</i> , 2020, 38, 567-575.	1.6	122
20	Cutaneous melanoma: available therapy for metastatic disease. <i>Dermatologic Therapy</i> , 2006, 19, 19-25.	1.7	121
21	Practical guidelines for the management of interferon- $\alpha$ 2b side effects in patients receiving adjuvant treatment for melanoma. <i>Cancer</i> , 2008, 112, 982-994.	4.1	116
22	IFN- $\alpha$ in the Treatment of Melanoma. <i>Journal of Immunology</i> , 2012, 189, 3789-3793.	0.8	112
23	Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9507-9507.	1.6	106
24	Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694. <i>Journal of Clinical Oncology</i> , 2009, 27, 38-44.	1.6	105
25	A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). <i>Cancer</i> , 2017, 123, 2688-2697.	4.1	103
26	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). <i>Journal of Clinical Oncology</i> , 2015, 33, 4066-4076.	1.6	101
27	Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. <i>Melanoma Management</i> , 2017, 4, 13-37.	0.5	97
28	A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. <i>Cancer</i> , 2009, 115, 859-868.	4.1	96
29	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	17.0	89
30	Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. <i>Clinical Cancer Research</i> , 2011, 17, 6574-6581.	7.0	77
31	CTLA-4 blockade: therapeutic potential in cancer treatments. <i>OncoTargets and Therapy</i> , 2010, 3, 15.	2.0	67
32	Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon- $\alpha$ or TLR-9 Agonist and GM-CSF With Peptide Vaccination. <i>Journal of Immunotherapy</i> , 2012, 35, 702-710.	2.4	63
33	A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer. <i>Human Gene Therapy</i> , 2011, 22, 336-342.	2.7	60
34	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
35	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	7.7	58
36	Tremelimumab: a review of development to date in solid tumors. <i>Immunotherapy</i> , 2013, 5, 215-229.	2.0	55

#	ARTICLE	IF	CITATIONS
37	Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3450-3458.	1.6	55
38	Management of brain metastases in patients with melanoma. <i>Current Opinion in Oncology</i> , 2004, 16, 161-166.	2.4	54
39	Safety and Immunogenicity of Vaccination With MART-1 (26â€“35, 27L), gp100 (209â€“217, 210M), and Tyrosinase (368â€“376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 359-366.	2.4	53
40	Neoadjuvant ipilimumab (3Âmg/kg or 10Âmg/kg) and high dose IFN-Î±2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. , 2018, 6, 112.		50
41	Adjuvant Therapy for Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2012, 18, 192-202.	2.0	47
42	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
43	A four-marker signature of TNF-RII, TGF-Î±, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. <i>Journal of Translational Medicine</i> , 2014, 12, 19.	4.4	42
44	Phase III Randomized Study of 4 Weeks of High-Dose Interferon-Î±2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Groupâ€“American College of Radiology Imaging Network Cancer Research Group (E1697). <i>Journal of Clinical Oncology</i> , 2017, 35, 885-892.	1.6	42
45	Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. <i>Clinics in Dermatology</i> , 2013, 31, 237-250.	1.6	40
46	Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1583-1593.	3.1	38
47	Clinical and Immunologic Basis of Interferon Therapy in Melanoma. <i>Annals of the New York Academy of Sciences</i> , 2009, 1182, 47-57.	3.8	36
48	Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced nonâ€“small cell lung cancer. <i>Cancer</i> , 2017, 123, 2936-2944.	4.1	36
49	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. <i>Journal of Translational Medicine</i> , 2018, 16, 184.	4.4	36
50	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	7.0	36
51	Immune Checkpoint Blockade and Interferon-Î± in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 436-447.	2.2	34
52	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	7.0	34
53	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9503-9503.	1.6	34
54	Oblimersen in the treatment of metastatic melanoma. <i>Future Oncology</i> , 2007, 3, 263-271.	2.4	32

#	ARTICLE	IF	CITATIONS
55	Adjuvant Pembrolizumab versus IFN $\alpha$ 2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	9.4	32
56	Multiple antigen-engineered DC vaccines with or without IFN $\alpha$ to promote antitumor immunity in melanoma. , 2019, 7, 113.		31
57	Interleukin-2 for the treatment of melanoma. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 1234-9.	2.3	31
58	Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. <i>Oncolmmunology</i> , 2017, 6, e1231291.	4.6	29
59	Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2019, 11, 617-629.	2.0	29
60	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 319.	4.4	27
61	Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2017, 19, 36.	4.0	26
62	Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. <i>Anticancer Research</i> , 2013, 33, 4475-81.	1.1	26
63	Biomarkers of Therapeutic Response in Melanoma and Renal Cell Carcinoma: Potential Inroads to Improved Immunotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 2583-2585.	1.6	24
64	Clinical and economic outcomes associated with treatment sequences in patients with <i>BRAF</i> -mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	2.0	24
65	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675.		24
66	Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 618-628.	1.2	23
67	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608.. <i>Journal of Clinical Oncology</i> , 2013, 31, CRA9007-CRA9007.	1.6	23
68	Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. <i>Cancer</i> , 2008, 112, 1131-1138.	4.1	22
69	A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. <i>Cancer</i> , 2008, 113, 1632-1640.	4.1	22
70	Neoadjuvant therapy for high-risk bulky regional melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 386-390.	1.7	22
71	Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. , 2016, 4, 38.		22
72	The impact of CTLA-4 blockade and interferon- $\alpha$ on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients. <i>Oncolmmunology</i> , 2019, 8, e1652538.	4.6	22

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant therapy of locally/regionally advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986695.	3.2	21
74	Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. <i>Immunotherapy</i> , 2018, 10, 1241-1252.	2.0	19
75	How Much of a Good Thing? What Duration for Interferon Alfa-2b Adjuvant Therapy?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3773-3776.	1.6	18
76	Neoadjuvant Pembrolizumab and High-Dose IFN-2b in Resectable Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4195-4204.	7.0	18
77	Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 461-473.	1.4	16
78	Safety and efficacy of the antiganglioside GD3 antibody ecomeximab (KW2871) combined with high-dose interferon-2b in patients with metastatic melanoma. <i>Melanoma Research</i> , 2017, 27, 342-350.	1.2	15
79	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	4.1	15
80	United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-2b for resected high-risk melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 9504-9504.	1.6	15
81	Surviving with lung cancer: Medication-taking and oral targeted therapy. <i>Geriatric Nursing</i> , 2014, 35, S49-S56.	1.9	14
82	A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma. <i>ESMO Open</i> , 2021, 6, 100050.	4.5	14
83	Novel agents in development for the treatment of melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 885-892.	4.1	13
84	Adjuvant Therapy: Melanoma. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-19.	1.2	13
85	Melanoma Adjuvant Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 471-489.	2.2	13
86	Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFN-2b in melanoma. <i>Translational Oncology</i> , 2021, 14, 101014.	3.7	13
87	Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. <i>Journal of Clinical Oncology</i> , 2021, 9, e002535.		13
88	Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. <i>Melanoma Research</i> , 2014, 24, 150-157.	1.2	12
89	The current state of adjuvant therapy of melanoma. <i>Lancet Oncology</i> , The, 2020, 21, 1394-1395.	10.7	12
90	Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. <i>Future Oncology</i> , 2019, 15, 359-370.	2.4	11

#	ARTICLE	IF	CITATIONS
91	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- $\beta$ but Not Observation in Intermediate Risk Melanoma Patients. PLoS ONE, 2015, 10, e0132745.	2.5	9
92	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. Journal of Translational Medicine, 2017, 15, 39.	4.4	9
93	Immunotherapy of Melanoma. Current Molecular Pharmacology, 2016, 9, 196-207.	1.5	9
94	Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Current Opinion in Molecular Therapeutics, 2007, 9, 505-14.	2.8	9
95	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e535-e542.	3.8	8
96	E3611â€”A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon- $\beta$ 2b in Advanced Melanoma. Clinical Cancer Research, 2019, 25, 524-532.	7.0	8
97	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy, 2021, 13, 1011-1029.	2.0	8
98	Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus ipi alone in metastatic melanoma: E1608.. Journal of Clinical Oncology, 2013, 31, CRA9007-CRA9007.	1.6	8
99	Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN- $\beta$ 2b in locally/regionally advanced melanoma.. Journal of Clinical Oncology, 2018, 36, 181-181.	1.6	8
100	Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. Molecular Carcinogenesis, 0, , .	2.7	8
101	Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash. Oncologist, 2019, 24, 4-8.	3.7	7
102	CTLA-4 blockade and interferon- $\beta$ induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS ONE, 2021, 16, e0245287.	2.5	7
103	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660.	3.8	7
104	CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology, 2010, 24, 1302, 1304.	0.5	7
105	Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. Expert Opinion on Drug Discovery, 2009, 4, 587-603.	5.0	6
106	Comprehensive Reporting in Cost-Effectiveness Modeling. Journal of Clinical Oncology, 2017, 35, 3085-3086.	1.6	6
107	Melanoma adjuvant therapy. Chinese Clinical Oncology, 2014, 3, 26.	1.2	6
108	Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. , 2022, 10, e004310.		6

#	ARTICLE	IF	CITATIONS
109	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660.	3.8	5
110	Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. Journal of Comparative Effectiveness Research, 2019, 8, 1349-1363.	1.4	5
111	Multidisciplinary Care of<sc><i>BRAF</i>-Mutant</sc>Stage<sc>III</sc>Melanoma: A Physicians Perspective Review. Oncologist, 2021, 26, e1644-e1651.	3.7	5
112	Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.. Journal of Clinical Oncology, 2016, 34, 9585-9585.	1.6	5
113	Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. Journal of Translational Medicine, 2022, 20, .	4.4	5
114	Vaccine therapy + dasatinib for the treatment of patients with stage III&IV melanoma. Melanoma Management, 2016, 3, 251-254.	0.5	4
115	Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncology, 2021, 17, 2151-2167.	2.4	4
116	Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, e19065-e19065.	1.6	3
117	The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 95-104.	4.1	3
118	Adjuvant Therapy of Melanoma. Hematology/Oncology Clinics of North America, 2021, 35, 73-84.	2.2	2
119	High-dose interleukin-2 (HD IL-2) in the treatment of advanced melanoma: The University of Pittsburgh experience.. Journal of Clinical Oncology, 2013, 31, 9075-9075.	1.6	2
120	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).. Journal of Clinical Oncology, 2012, 30, 8522-8522.	1.6	2
121	Early Cortisol and Inflammatory Responses to Parental Cancer and Their Impact on Functional Impairment in Youth. Journal of Clinical Medicine, 2021, 10, 576.	2.4	1
122	Abstract 2911: Immune related melanoma gene expression profile predicts neoadjuvant ipilimumab clinical benefit. , 2014, , .		1
123	Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity.. Journal of Clinical Oncology, 2014, 32, 9024-9024.	1.6	1
124	Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis.. Journal of Clinical Oncology, 2020, 38, 60-60.	1.6	1
125	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. , 2012, , 305-317.		1
126	Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease. , 0, , 313-324.		0



#	ARTICLE	IF	CITATIONS
127	Uveal Melanoma: Metastases. , 2019, , 317-329.		0
128	Pilot evaluation of sulforaphane in melanoma patients with multiple atypical nevi: Tissue STAT1 and STAT3 as risk markers.. Journal of Clinical Oncology, 2012, 30, TPS8606-TPS8606.	1.6	0
129	Phase II study of the anti-gangliosideÂGD3 mouse/human chimeric antibody KW2871 combined with high dose interferon-a2b in patients with metastatic melanoma.. Journal of Clinical Oncology, 2012, 30, 8547-8547.	1.6	0
130	Association of high T-cell immune infiltrate and low hemorrhage in melanoma brain metastases (MBMs) with prolonged survival.. Journal of Clinical Oncology, 2012, 30, 8528-8528.	1.6	0
131	Differential genomic profiles of tumor-involved and tumor-free sentinel lymph nodes in patients with melanoma.. Journal of Clinical Oncology, 2013, 31, 9043-9043.	1.6	0
132	Phase II study of low-dose peginterferon alfa-2b antiangiogenic therapy in patients with metastatic melanoma overexpressing basic fibroblast growth factor: An Eastern Cooperative Oncology Group study (E2602).. Journal of Clinical Oncology, 2013, 31, 9038-9038.	1.6	0
133	T-regulatory cell function analysis in locally/regionally advanced melanoma patients treated with ipilimumab.. Journal of Clinical Oncology, 2013, 31, 3041-3041.	1.6	0
134	A unique gene expression signature in tumor positive or negative sentinel lymph nodes in patients with melanoma.. Journal of Clinical Oncology, 2014, 32, 9087-9087.	1.6	0
135	NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanomaâ€Efficacy and biomarker study.. Journal of Clinical Oncology, 2014, 32, TPS9120-TPS9120.	1.6	0
136	Prognostic significance of sentinel lymph node biopsies (SLNB) in melanoma.. Journal of Clinical Oncology, 2014, 32, e20029-e20029.	1.6	0
137	Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN-Î±. , 2016, , 49-63.		0
138	Despite past disappointments, the future of melanoma therapy appears bright. Oncology, 2009, 23, 509, 515.	0.5	0